TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AstraZeneca ( (AZN) ) has provided an update.
On December 2, 2025, The Capital Group Companies, Inc. adjusted its holdings in AstraZeneca PLC, reducing its voting rights from 5.017815% to 4.973499%. This change reflects a minor adjustment in the investment management company’s stake, which could have implications for AstraZeneca’s shareholder dynamics and influence within the company.
The most recent analyst rating on (AZN) stock is a Buy with a $103.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call drive a high overall score. The bullish technical indicators support this, though the high valuation and potential challenges in China and Medicare reforms temper the outlook.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca PLC is a UK-based pharmaceutical company that specializes in the research, development, and manufacturing of prescription medicines. The company focuses on areas such as oncology, cardiovascular, renal, metabolism, respiratory, immunology, and rare diseases.
Average Trading Volume: 5,123,699
Technical Sentiment Signal: Buy
Current Market Cap: $285.4B
Learn more about AZN stock on TipRanks’ Stock Analysis page.